GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » YoY Rev. per Sh. Growth

New Ray Medicine International Holding (HKSE:06108) YoY Rev. per Sh. Growth : -177.78% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. New Ray Medicine International Holding's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was -177.78%.

New Ray Medicine International Holding's Revenue per Share for the six months ended in Dec. 2023 was HK$-0.01.


New Ray Medicine International Holding YoY Rev. per Sh. Growth Historical Data

The historical data trend for New Ray Medicine International Holding's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding YoY Rev. per Sh. Growth Chart

New Ray Medicine International Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.16 12.68 151.25 -73.13 -44.44

New Ray Medicine International Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.47 -72.66 -75.00 25.71 -177.78

New Ray Medicine International Holding YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

New Ray Medicine International Holding's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0.03-0.054)/ | 0.054 |
=-44.44 %

New Ray Medicine International Holding's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(-0.014-0.018)/ | 0.018 |
=-177.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


New Ray Medicine International Holding YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines